

Index

A

- Acceleration phase, 346
- Acetylcholinesterase, 279
- Acetylsalicylic acid, 465–466
- Acrofacial vitiligo (AFV), 13, 45
- Afamelanotide, 9, 374
- Aging
 - in childhood
 - medical treatment, 439–440
 - phototherapy, 440–441
 - psychosocial aspects, 442
 - surgical treatment, 441–442
 - in older adults, 442
 - psychological impact, 438
- Alabras, 5
- Alexithymia, 175
- Alezzandrini syndrome, 109
- Allergic contact dermatitis, 122
- All-trans retinoic acid (ATRA), 384
- Alopecia areata, 126, 127
- Alopecia areata-like feathering defect, 213
- Ammi majus Linnaeus* (AML), 7–9
- Animal models
 - mouse models
 - FH mouse, 218
 - h3T-A2 mouse, 218–219
 - Krt14-Kitl* mouse-pmel-1 T cell adoptive transfer model, 217–218
 - melanocyte-specific immune responses, 214–215
 - Pmel-1 mouse, 217
 - TCR transgenic hosts, 215–219
 - TrpHEL mouse, 218
 - TRP1 transgenic mouse, 218
 - vitesse mouse, 219
 - naturally occurring vitiligo, 207
 - Smyth line (SL) chicken
 - alopecia areata-like feathering defect, 213
 - autoimmune hypothyroiditis, 212
 - avian model, 213
 - blindness, 212
 - characteristics, 207
 - environmental factor, 211–212
 - genetics basis, 208–209
 - immune system, 209–211
 - impaired vision, 212
 - inherent melanocyte alterations, 211
 - spontaneous autoimmune vitiligo, 207–209
 - uveitis, 212
 - water buffalo, 213
- Annular lichenoid dermatitis of youth (ALDY), 84, 85
- Antigen-presenting cells (APCs), 288–289
- Anti-IFN- α approach, 369–370
- Anti-IFN- γ strategy, 369
- Antioxidants, 279, 364–365
 - combined therapies, 348
 - intracellular network, 340
 - occurrence, 414–415
 - Polypodium leucotomos*, 415
- Anti-PD-1 therapies, 164–166
- Anti-TNF- α strategy, 295
- APECED, *see* Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy
- APS, *see* Autoimmune polyendocrine syndrome
- Aspirin, 465–466
- Assessment
 - chronic autoimmune/inflammatory diseases, 172
 - interobserver variability, 174–175
 - scoring system, 172–174
 - skin biopsy, 172
 - variables, 175
- Ataxia-Telangiectasia (AT) syndrome, 136–137
- Atharva Veda, 4
- Autoantibodies against aromatic l-amino acid decarboxylase (AADC), 134
- AutoCAD 2000, 197
- Autoimmune/inflammatory diseases, 172
- Autoimmune polyendocrine syndrome (APS), 134–136, 172, 239
- Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), 134, 135, 183
- Autoimmune regulator (AIRE), 134
- Autoinflammatory/autoimmune diseases
 - alopecia areata, 126, 127
 - atopic diseases, 128
 - autoimmune thyroiditis, 126, 128
 - combinatorial pathogenic effects, 126
 - epidemiological studies, 126, 128
 - follicular vitiligo, 128
 - Hashimoto's thyroiditis, 127

Autoinflammatory/autoimmune diseases (*cont.*)

- immunodeficiencies
 - B-cell deficiencies, 132
 - combined/T-cell immunodeficiencies, 128
 - CVID, 128, 131
 - heterozygous C4 deficiency, 132
 - HIV infection, 126, 128–131
 - ICTL, 131
 - IRIS, 131
 - oxidative stress dysregulation, 129
- monogenic disorders, 132, 133
 - AADC, 134
 - AIRE, 134
 - APECED/APS1, 134, 135
 - autoimmune polyendocrine syndromes, 134–136
 - autosomal dominant vitiligo, 132
 - breakage disorders, 136–138
 - mitochondrial disorders, 136
 - organ-specific autoimmunity, 134
 - piebaldism, 132
 - Val620Ala mutation, 132
 - vitiligo patches, 132
 - vitiligo-related phenotypes, 132
- prevalence, 127
- psoriasis, 128
- 5-Azacytidine (5-azaC), 259

B

- Baker-Gordon's formula, 385
- Baras, 5
- Basal membrane, 34
- Basic fibroblast growth factor (bFGF), 383, 384
- Bcl-2 protein family, 280
- β -catenin, 268
- Bilateral mosaicism, 78–79
- Blaschkoid hypopigmentation, 335
- Bloom syndrome (BS), 138
- Blue vitiligo, 45
- Bone marrow (BM), 315, 317
- Bordeaux VGICC classification, 12, 14
- Breakage disorders, 136–138

C

- Cadherin (cell adhesion), 228, 268, 269
- Calcineurin inhibitors, 348, 351–354
- Calcipotriol, 363, 440
- Calcitriol, 440
- Calreticulin, 233
- Camouflage
 - cosmetic rehabilitation, 422
 - cover creams, foundations and sticks, 425–426
 - DHA, 424
 - guidelines, 474
 - history, 423–424
 - intervention, 422–423
 - leukotrichia, 426
 - permanent and semi-permanent camouflage, 426
 - precautions, 426–427
 - self-tanning creams, lotions and sprays, 424–425

- transfer-resistant lip colour, 426
- treatments, 346–349
- WHO, 422
- cAMP response element-binding protein (CREB), 279
- Candidate gene approach, 240–241
- Cavities, 95, 97
- Cardiac melanocytes, 109
- Catecholamines, 278
- CD4+CD25+Foxp3+ regulatory T (Treg) cells, 257
- CD8+ T-cells, 122, 128, 165, 305
- Cell isolation and culture
 - Eagle's minimal essential medium, 227
 - fibroblasts, 227
 - hair follicle keratinocytes, 227–228
 - hair follicle melanocyte, 227–228
 - hydrogels, 228
 - keratinocytes, 226–227
 - melanocytes, 226–227
 - PBMC, 228
 - transgenesis, 228
- CellnTechn-07 (Chemicon), 227
- Cellular immunity, 291–292
- Cephalic melanocytes, 108–109
- Charak, 4
- Chemically induced vitiligo, 122
- Childhood vitiligo
 - and autoimmune thyroid disorders, 145
 - clinical features, 144
 - differential diagnosis, 145
 - early-onset group, 144
 - epidemiology of, 142–143
 - family history, 144–145
 - later-onset group, 144
 - NSV vitiligo, 143
 - post-pubertal onset, 144
 - prepubertal onset, 144
 - prevalence of, 142
 - psychological morbidity, 145
 - quality of life, 145
 - segmental vitiligo, 143
 - therapeutic considerations, 146
 - treatment, 144
 - on trunk and groin, 143
- Cholera toxin (CT), 383
- Chroma Meter CR 200/CR 300, 198, 199
- CHS, *see* Contact hypersensitivity
- CIV, *see* Clinically inflammatory vitiligo
- Classical melanocytes, 266
- Classic oculocutaneous albinism, 17
- Clinical aspects, 39
- Clinical evaluation
 - autoimmune/inflammatory disorders, 170, 172
 - checklist for NSV, 171
 - clinical data, 184
 - hair graying, 170, 171
 - importance, 182
 - predictive assessment, 183
 - systematic pathology assessment, 183
 - Wood's lamp examination, 170, 171
- Clinically inflammatory vitiligo (CIV)
 - clinical features and presentation, 82, 83

- confetti-like leukoderma, 89
 - differential diagnosis, 82, 85
 - follicular vitiligo, 85, 88
 - histopathological examination, 84–85
 - hypochromic vitiligo/vitiligo minor, 88–89
 - leukoderma punctata, 89
 - marginal hyperpigmentation, 83
 - nummular lichenoid lesions, 83
 - other infectious/inflammatory diseases, 83
 - patient history, 83–84
 - and psoriasis, 82
 - PUVASOL therapy, 89
 - with raised borders, 82
 - symptoms and signs, 82
 - vitiligo guttata/punctata, 89
 - Clobetasol propionate, 439
 - Collagen-glycosaminoglycan-chitosan, 229
 - Combined therapy, 347, 386
 - dermabrasion/fractional ablative lasers, 415–416
 - maintenance therapy, 416–417
 - phototherapy
 - and antioxidants, 414–415
 - and TCI, 413–414
 - and topical steroids, 412–413
 - and vitamin D, 414
 - surgical therapies and corticosteroids, 412
 - surgical therapies and phototherapy, 412
 - Common variable immunodeficiency (CVID), 128, 131
 - Computerized digital image analysis system, 197
 - Contact hypersensitivity (CHS), 122–123
 - Contact vitiligo, 122
 - Corel Draw 9.0, 197
 - Corrective makeup workshops, 455–456
 - Corticosteroids, 347–348, 412
 - See also* Topical corticosteroids
 - Counseling, 349
 - CpG islands, 258–259
 - CIq and tumor necrosis factor-related protein (CIQTNF6), 287
 - Crohn's disease, 272, 273
 - Cryotherapy, 387
 - CTLA4* gene, 241
 - Cultured epidermal sheet transplantation, 384–385
 - Cultured melanocyte transplantation, 383–384
 - Cutaneous disorder, 458
 - Cutaneous mosaicism, 22, 58, 191
 - CVID, *see* Common variable immunodeficiency
 - CXCR3 chemokine receptor, 165
 - Cyclophosphamide, 48
 - Cytokine & Cells Online Pathfinder Encyclopedia (COPE) website, 234
 - Cytokines, *see* Proinflammatory cytokines
 - Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), 164, 260
- D**
- Damage-associated molecular patterns (DAMPs), 248, 249
 - Dead de-epidermized dermis (DDD), 229
 - Decay-accelerating factor (DAF), 286
 - Deep phenotyping, 182, 183
 - Delayedamelanotic (DAM) chicken, 208
 - Dental pulp stem cells (DPSCs), 314
 - Depigmenting therapy, 379–389
 - cryotherapy, 387
 - DPCP, 388–389
 - extensive and universal vitiligo, 380
 - guidelines, 482
 - hydroquinone, 380
 - imatinib, 388
 - imiquimod, 388
 - laser therapy, 385–386
 - MBEH, 386
 - ATRA, 384
 - definition, 381
 - mechanism of action, 383
 - precautions, 383–384
 - side effects, 384
 - treatment procedure, 384
 - 4-0 methoxyphenol, 384–385
 - patient selection, 380–381
 - 88% phenol solution, 385
 - QSA laser, 386–387
 - QSR laser, 386
 - stabilization, 475–476
 - Depression, 175, 178
 - Dermapabrasion/fractional ablative lasers, 415–416
 - Dermal components, 330
 - DermaSpectrometer, 199
 - Dermatology Life Quality Index (DLQI), 154, 179
 - Dermis, 34–35
 - Dermis-derived stem cells (DSCs), 325
 - Dermoscopy, 199, 203
 - Detachment process, 330–331
 - Dicer, 256, 257
 - Differential diagnosis
 - hypopigmented mycosis fungoides, 35
 - inherited/genetically induced hypomelanoses
 - hypomelanosis of Ito, 14, 18
 - monogenic hypomelanoses, 14, 15
 - piebaldism, 14–15, 17
 - tuberous sclerosis, 15, 17
 - Waardenburg's syndrome, 15, 18
 - melanoma-associated depigmentation, 19, 20
 - melasma, 21, 22
 - microscopical features, 35
 - morphologic abnormalities, 35
 - nevus depigmentosus, 22, 23
 - occupational and drug-induced depigmentation, 22
 - para-infectious hypopigmentation, 20–21
 - para-malignant hypomelanoses, 19, 20
 - psoriasis alba, 35
 - post-inflammatory hypomelanoses, 18, 19
 - posttraumatic leukoderma, 21
 - Digital epiluminescence dermoscopy, 199
 - Digital image analysis, 197–198
 - Digital photographs, 197
 - Dihydroxyacetone (DHA), 349, 424
 - Diphencyprone (DPCP), 388–389
 - DLQI, *see* Dermatology Life Quality Index

DNA methylation, epigenetics
 in animal models, 259
 CpG islands, 258–259
 in human vitiligo, 259–260
 DNA methyltransferase (DNMT), 258, 259
 DOPA-stained skin sheets, 9
 Dorsolateral pathway, 266, 267
 Dulbecco's Modified Eagle's Medium (DMEM), 394

E

Eagle's minimal essential medium, 227
Ebers Papyrus, 3, 4, 7
 EBM guidelines, 482
 E-cadherin, 268, 269, 271–274
 Electron microscopy, 32
 Embryonic stem (ES), 314
 EMU, *see* Epidermal melanin unit
 Endothelin-3 (ET-3), 319, 320
 Environmental factors, 121, 122
 Epidemiological data, 182
 Epidermal melanin unit (EMU), 229, 269–271
 Epidermal melanocytic target, 184
 Epidermal naevi, 335
 Epidermal pigmentation, 65, 194, 219, 305, 306, 331
 Epigenetics
 definition, 254
 disorders of, 254
 DNA methylation
 in animal models, 259
 CpG islands, 258–259
 in human vitiligo, 259–260
 environmental factors, 261, 262
 histone modifications
 in autoimmune diseases, 260–261
 chromatin modification in melanocyte
 differentiation, 261
 histone acetylation, 260–261
 histone methylation, 260–261
 miRNAs in melanogenesis
 biogenesis and function, 254–255
 immune tolerance regulation, 256–257
 miR-145, 256
 miRNA dysregulation, 257–258
 MITF, 256
 solar-simulated UV, 256
 UVR, 256
 Epigenome editing, 230, 231
 Erythema index (EI), 198
 Evidence-based guidelines, 349
 Extracellular matrix (ECM) proteins, 330
 Extra-cutaneous melanocytes
 Alezzandrini syndrome, 109
 cardiac melanocytes, 109
 cephalic melanocytes, 108–109
 distribution of melanocytes in human tissues, 104
 in hereditary pigmentary disorders, 109
 lymphangioliomyomatosis, 109
 melanin biosynthesis, 109
 ocular melanocytes, 105–106

otic melanocytes, 107–108
 types, differences, and changes, 110
 VKH syndrome, 109
 Waardenburg syndrome, 109

F

Fetal calf serum (FCS), 383
 FH TCR transgenic mouse vitiligo model, 218
 Fibroblasts, 190, 191
 Fine-needle sampling (FNS), 233
 Fitzpatrick's system, 430
 Fluorescence resonance energy transfer (FRET) analysis,
 233
 Fluorochrome-conjugated monoclonal antibodies, 232
 5-Fluorouracil (5-FU), 415, 466–467
 Fluticasone, 352
 Fluticasone propionate (FP), 352
 Focal vitiligo, 14
 Follicular melanogenesis, 96
 Follicular unit extraction (FUE), 394
 Follicular vitiligo, 14, 85, 88, 128
 Fontana–Masson staining, 26, 323
 Forkhead box protein O1 (FOXO1), 279
 FOXD3 transcriptional promoter, 243
 Free radical-mediated graying, 340

G

Gender, 462
 Generalized vitiligo
 blue vitiligo, 45
 depigmentation, 42, 43
 distribution of, 43–44
 hyperpigmented lesional borders, 42
 multichrome vitiligo, 44–45
 natural course, 44
 symmetrical lesions, 42, 43
 symptoms, 42
 Wood's lamp examination, 43, 44
 Genetically modified cells in monolayer, 230
 Genetic factors, 122
 Genetics
 bioinformatic functional interaction network of
 proteins, 247
 candidate gene approach, 240–241
 DAMPs, 249
 epidemiology
 autoimmune diseases, 239, 240
 autoimmune polyendocrine syndrome, 239
 EUR population, 238, 241
 Han Chinese families, 239
 males and females, 238
 twin studies, 239
 genome-wide approach, 241–242
 genome-wide association studies, 243–246
 genome-wide linkage studies, 242–243
 purpose of gene identification, 246–247
 vitiligo and melanoma relationship, 246
 vitiligo pathogenesis framework, 248

- Genital vitiligo, 446
- Genome-wide association studies (GWAS), 243–246
- Genome-wide genetic approach, 241–242
- Genome-wide linkage studies, 242–243
- Ginkgo biloba*, 465
- Global assessment scale (GAS), 196, 197
- Graft versus host disease (GVHD), 84
- Graves' disease, 126, 127, 135, 172, 242
- Growth factor
- bFGF protein levels, 307
 - granulocyte-macrophage colony-stimulating factor, 270, 306, 307
 - hepatocyte growth factor, 306
 - keratinocytes, 306
 - microphthalmia-associated transcription factor, 306
- Guillet-Westerhof syndrome, 21
- H**
- Hair follicle keratinocytes (HFk), 227
- Hair follicle melanocyte (HFM) culture, 227–228
- Hair follicles, 339
- Hair graying, 170
- Halo nevus
- clinical features, 94–95
 - diagnosis, 100
 - histopathology, 97–98
 - hydrogen peroxide concentration, 99
 - with non-segmental vitiligo, 99
 - pathogenesis, 96
 - treatment, 100
 - with Vogt-Koyanagi-Harada syndrome, 99
- Hank's balanced salt solution, 229
- Harvesting epidermal cells, 412
- Hashimoto's autoimmune thyroiditis, 259
- Hashimoto's thyroiditis, 94, 126, 127, 131, 145, 172, 212, 259, 287, 346
- Heat shock proteins (HSPs), 289–290
- Hemicorporeal hypomelanosis of Ito, 18, 22
- Hepatocyte growth factor (HGF), 330
- Hereditary pigmentary disorders, 109
- Herodotus, 7
- Highly active antiretroviral treatment (HAART), 130
- High phototypes
- leukotrichia, 443
 - medical treatment, 443–444
 - prevalence, 442
 - surgery, 444–445
 - vitiligo phobia, 445
- Histone acetylation, 260
- Histone acetyltransferases (HATs), 260
- Histone deacetylases (HDACs), 260
- Histone demethylase (HDMs), 260
- Histone methylation, 260
- Histone methyltransferases (HTMs), 260
- Histone modifications
- in autoimmune diseases, 260–261
 - chromatin modification in melanocyte differentiation, 261
 - histone acetylation, 260
 - histone methylation, 260
- Histopathology
- amelanotic lesions, 30
 - basal layer vacuolization, 30
 - biopsy site selection, 26
 - epidermal and dermal changes, 26, 30
 - epidermal-clustered lymphocytes, 28
 - focal spongiosis, 28
 - follicular melanocytes, 28
 - Fontana-Masson silver staining, 26
 - functional melanin-producing melanocytes, 26, 27
 - marginal melanocytes, 28
 - melanophages, 30
 - of normal-appearing skin, 30–31
 - phototherapy, 30
 - pro-melanogenic mediators, 30
 - reparative/protective phenomenon, 29, 30
 - residual melanocytes, 28
 - spongiosis, 30
 - of stable lesional vitiligo, 26, 27
 - vacuolar degeneration, 29
- HIV infection-associated inflammatory vitiligo, 84
- H3K9 acetylation (H3K9Ac), 260
- HLA* alleles, 241
- HLA-DQB1* gene expression, 260
- H3T-A2 mouse model, 218–219
- Human leukocyte antigens (HLA)-A2, 287
- Human Protein Atlas (HPA), 234
- Hydrogels, 228
- Hydrophobic interaction chromatography (HIC), 234
- Hydroquinone (HQ), 381
- p*-Hydroxyanisole (HA), 384
- 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), 466
- Hypochromic vitiligo/vitiligo minor, 88–89
- Hypothalamic-pituitary-adrenal, 307
- I**
- IADVL Dermatosurgery Task Force, 349
- “Ideal observer” method, 174, 175
- Idiopathic CD4+ T-cell lymphocytopenia (ICTL), 131
- IL-10 gene, 259
- Image-Pro Plus 4.5, 197
- Imatinib, 388
- Imiquimod, 388
- Immune reconstitution inflammatory syndrome (IRIS), 131
- Immunity/immunopathology
- antigen-presenting cells, 288–289
 - autoimmune disease, 286–287
 - cellular immunity, 287–288
 - cytokine inhibition, 295
 - environmental factors, 287
 - heat shock proteins, 289–290
 - HSP70+ exosomes, 291–292
 - inhibiting T cell recruitment, 294
 - JAK inhibitors, 294
 - melanoma T cell responses, 295
 - modified HSP70, 293–294

- Immunity/immunopathology (*cont.*)
 morphology of cultured melanocytes, 286
 phototherapy, 292–293
 T cell subset imbalance, 290
 T cell trafficking, 290–291
 toll-like receptors, 291
 Treg-based therapy, 294–295
- Immunohistochemistry, 31–32
- Immunosuppressants, 476, 482
- Immunosuppressive systemic therapies
 anti-IFN- α approach, 369–370
 anti-IFN- γ strategy, 369
 classic immunosuppressants, 371
 corticosteroids
 oral minipulse, 366–368
 pulse corticosteroids, 366
 side effects, 366
 immunomodulators, 368
 JAK inhibitors, 371
 systemic immunosuppressants, 368
 T cell skin recruitment blocking strategy, 370–371
 TNF- α antibodies, 371
- Independent component analysis, 197
- Indeterminate leprosy, 20
- Induced pluripotent stem (iPS) cells, 314
- Inflammatory infiltrate, 32
- Inherited/genetically induced hypomelanoses
 classic oculocutaneous albinism, 17
 hypomelanosis of Ito, 14, 18
 monogenic hypomelanoses, 14, 15
 piebaldism, 14–17
 tuberous sclerosis, 14, 17
 Waardenburg's syndrome, 14, 18
- Innate immunity hypothesis, 341
- Integra[®], 229
- Integrin expression, 330
- Intercellular adhesion molecule (ICAM)-1, 352
- Interleukin-1 β (IL-1 β) inflammatory pathway, 243
- Interleukin-2 receptor alpha chain (IL2RA), 287
- International Consensus, 13
- Interobserver variability, 174–175
- Invariant natural killer T (iNKT) cells, 257
- In vitro study
 analytic techniques
 fluorescence-based assays, 232–233
 lipidomics, 234
 metabolomics, 234
 proteomic assay, 233–234
 transcriptomics, 235
 cell isolation and culture
 Eagle's minimal essential medium, 227
 fibroblasts, 227
 hair follicle keratinocytes, 227–228
 hair follicle melanocyte, 227–228
 hydrogels, 228
 keratinocytes, 226–227
 melanocytes, 226–227
 PBMC, 228
 transgenesis, 228
 epidermis reconstruction
 dead de-epidermized dermis, 229
 fibroblasts and collagen-glycosaminoglycan-chitosan, 229
 Langerhans cells, 229
 melanocytes and keratinocytes, 229
 functional studies
 chromatin modifications, 231
 epigenome editing, 230, 231
 genetically modified cells in monolayer, 230
 keratinocyte cultures, 229
 melanocyte cultures, 229
 reconstructed epidermis, 231–232
 single-cell epigenomics approach, 231
- In vivo confocal microscopy, 183
- In vivo reflectance confocal microscopy (RCM)
 concept, 199
 half rings/scalloped border-like rings, 201
 limitations, 194, 202
 papillary rings, 201, 202
 stability of vitiligo, 202
 UVB therapy, 201, 202
- Isobutylmethylxanthine (IBMX), 383
- J**
- Janus kinases (JAKs), 294
- K**
- Keratinocyte growth factor (KGF), 330
- Keratinocytes, 32–34, 190, 191
- Keratinocyte stem cells (KSCs), 267
- Khellin, 465
- Kilas, 4, 178
- Koebner phenomenon (KP), 13, 19, 98, 99, 165, 166, 184, 346
 classification, 115, 116
 assessment by patient history, 115
 by clinical examination, 115
 by lesions, 115
 clinical differentiation, 115
 clinical presentation, 117–119
 depigmentation, 116
 etiopathogenesis, 117
 on friction areas (Type 2A), 117
 incidence of, 115, 117
 melanocyte loss, 338–339
 mini-grafting test, 117
 post-inflammatory hypopigmentation, 118
 Wood's light examination, 118
- Krt14-Kitl* mouse-pmel-1 T cell adoptive transfer model, 217–218
- L**
- L*, a*, b* color parameters, 198
- Langerhans cells, 34, 229
- Laser scanning cytometer (LSC), 233

- Late-onset vitiligo
 clinical features, 148
 definition, 147
 and diabetes mellitus, 148–149
 epidemiology, 147–148
 therapeutic considerations, 149
- Lesional keratinocytes, 32, 230, 280, 330
- Leukoderma, 6
- Leukoderma punctata, 89
- Leukotrichia, 426, 443, 444
 clinical features, 95–96
 diagnosis, 100
 pathogenesis, 96–97
 treatment, 100–101
- Lipidomics, 234
- Liquid chromatography tandem-mass spectrometry (LC-MS/MS), 233
- Low self-esteem, 97, 178, 452
- Lymphangioliomyomatosis (LAM), 109
- M**
- M154 (Gibco), 227
- M254 (Gibco), 227
- “Maillard’s” reaction, 424
- Maintenance therapy, 416–417
- Major histocompatibility complex (MHC), 241
- Management-oriented evaluation, 346
- MatriDerm™, 229
- MBEH, *see* Monobenzyl ether of hydroquinone
- MCDB153 (Sigma), 227
- McSCs, *see* Melanocyte stem cells
- MED, *see* Minimal erythema dose
- Medical therapies
 antioxidants, 411–413
 calcineurin inhibitors, 351–354
 combination therapy, 352–353
- Melagenin, 465
- Melanin, 430
- Melanin index, 198
- Melanoblasts
 cadherins, 268, 269
 dorsolateral pathway, 266, 267
 dorsoventral pathway, 267
 keratinocyte stem cells, 267
 melanocyte progenitors migratory pathway, 266–267
 melanocyte stem cells, 267
 skin distribution and differentiation, 269
- Melanocyte homeostasis
 epidermal melanin unit, 269–270
 epidermal melanocyte renewal, 271
- Melanocyte loss, 338–339
- Melanocytes, 32, 34, 319–320, 325
- Melanocyte-specific T lymphocytes, 335
- Melanocyte stability
 E-cadherin and vitiligo, 271–274
 epidermal melanin unit, 271
- Melanocyte stem cells (McSCs), 267, 271, 273, 274
- Melanocyte stemness, 339–340
- Melanocytic targets, 182
- Melanoma-associated depigmentation, 19, 20
- Melasma, 21, 22
- Membrane lipids, 340–341
- Mesenchymal stem cell (MSC), 314, 315
- Metabolomics, 234
- Metastatic melanoma, 164–166
- 4-Methoxyphenol (MP), 384–385
- Methyl-CpG-binding domain (MBD) proteins, 259
- Mexameter, 199
- MGM4 BulletKit (Lonza), 227
- Microinflammation, 183
- Microphthalmia-associated transcription factor (MITF), 165, 256, 261, 279, 280, 319, 320
- Microvascular skin homing, 335
- Minimal erythema dose (MED), 347, 426
- Mini-punch grafting (MPG), 441, 445
- Minolta CR-200 Chroma Meter, 199
- miRNAs in melanogenesis
 biogenesis and function, 254–255
 immune tolerance regulation, 256–257
 miR-145, 256
 miRNA dysregulation, 257–258
 MITF, 256
 solar-simulated UV, 256
 UVR, 256
- MITF, *see* Microphthalmia-associated transcription factor
- Mitochondria, 136, 280
- Mitogen-activated protein kinase (MAPK), 279
- Mixed vitiligo (MV), 13, 59, 60
 bilateral mosaicism, 78–79
 clear segmental blaschkolinear pattern, 74
 definition, 74
 diagnosis, 76–77
 genetic link SV-vitiligo/NSV, 77–78
 halo nevi, 78
 leukotrichia, 78
 nonsegmental involvement, 74–76
 risk factors, 77
 segmental involvement, 74, 76
 therapeutic intervention, 74
 univariate analysis, 77
 UVB phototherapy, 76
 Wood’s lamp examination, 77
- M2 medium (PromoCell), 227
- Modified HSP70, 293–294
- Monobenzyl ether of hydroquinone (MBEH), 48, 387
 ATRA, 384
 definition, 421
 mechanism of action, 384
 vs. 4-methoxyphenol, 384–385
 vs. 88% phenol solution, 385
 precautions, 383–384
 side effects, 384
 treatment procedure, 383
- Monogenic hypomelanoses, 14, 15
- Mono-segmental vitiligo, 14

- Mouse models
 FH mouse, 218
 h3T-A2 mouse, 218–219
 Krt14-Kitl* mouse-pmel-1 T cell adoptive transfer model, 217–218
 melanocyte-specific immune responses, 214–215
 Pmel-1 mouse, 217
 TCR transgenic hosts, 215–219
 TrpHEL mouse, 218
 TRP1 transgenic mouse, 218
 vitesse mouse, 219
 MPG, *see* Mini-punch grafting
 MSC, *see* Mesenchymal stem cell
 Mucosal pigmentary system, 182
 Multichrome vitiligo, 44–45
 Multifactorial nature of autoimmune diseases, 206
 Multilineage-differentiating stress-enduring (Muse) cells
 in adult tissues, 314, 315
 BM-MSCs, 315, 316, 318–319
 characteristics
 non-tumorigenicity, 318
 pluripotency, 317–318
 SCID mice, 318
 sources, 317
 SSEA-3, 316–317
 fibroblasts, 318–319
 functional evaluation, 324–325
 future perspectives, 325
 hematopoietic stem cells, 315
 human-colored 3D-cultured skin, 322–323
 melanocytes, 319–320, 325
 non-Muse cells, 320–322
 propensity, 319
 somatic stem cells, 314–315
 Multisegmental vitiligo, 13
 MV, *see* Mixed vitiligo
 Mycosis fungoides, 19, 20
 Myoclonic epilepsy associated with ragged-red fibers (MERRF) syndrome, 136
 Myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome, 136
- N**
- Naevus cells, 183, 184
 Naevus depigmentosus, 335
 Narrowband UVB (NB-UVB), 146, 147, 157–159, 292, 347–348, 353, 362, 363, 412
 Natural psoralens, 8
 NBS, *see* Nijmegen breakage syndrome
 N-cadherin, 268, 271
 NCES, *see* Non-cultured epidermal cell suspension transplantation
 Neural crest cells (NCC), 266
 Neuronal theory, 191
 Neuropeptides, 179
 Nevus depigmentosus, 22, 23
 Nicotinamide adenine dinucleotide (NADH)-binding site, 279
- Nijmegen breakage syndrome (NBS), 137–138
 NLRP1 gene, 243
 Nonclassical melanocytes, 266
 Non-cultured epidermal cell suspension (NCES) transplantation, 385–389
 age, childhood in, 441
 basal cell layer suspension, 387
 culture medium and xenobiotics, 385–386
 donor skin, 386
 factors influencing outcome, 389–390
 hyaluronic acid, 387
 hypopigmentation, 386
 laser ablation, 386
 long-term follow-up, 386–387
 protocol, 395–396
 simplification, 390–392
 ultrathin epidermal graft, 388–389
 UVB stimulation, 387–388
 wound healing, 386
 Non-cultured outer root sheath hair follicle cell suspension (NCORSHFS), 392–395
 Non-lesional skin, metabolic profile, 279–280
 Non-melanoma skin cancers (NMSC), 432
 Non-Muse cells, 318–319
 Non-segmental vitiligo (NSV), 13, 45, 333, 340
 Normally pigmented skin, 35
 Nucleosome remodeling factor (NURF), 261
 Nummular lichenoid lesions, 83
- O**
- Occupational and drug-induced depigmentation, 22
 Occupational vitiligo, 122
 Ocular melanocytes
 eye anatomy, 105
 negative ocular electrophysiologic findings, 106
 ocular pigmentary changes, 106
 in retinal pigment epithelium, 105, 106
 in uveal tract, 105–106
 Oligonucleotide-based microarrays, 235
 Oral minipulse (OMP), 366–368
 Otic melanocytes, 107–108
 Outer root sheath (ORS), 392, 394
 Oxidative stress, 189, 190, 278–279
 Oxysterols, 330
- P**
- Para-aminobenzoic acid (PABA), 372, 434
 Para-infectious hypopigmentation, 20–21
 Para-malignant hypomelanoses, 19, 20
 Partial depigmentation, 46, 174, 386
 Pathogen-associated molecular patterns (PAMPs), 243
 Pathology, 183
 Pathophysiology
 animal models, 191
 environmental factors, 189
 genetic factors, 189
 in vitro approach, 191

- melanocyte loss, 189
 - mitochondrial dysfunction, 190
 - non-segmental vitiligo, 190, 191
 - oxidative stress, 189, 190
 - prooxidant/antioxidant status, 190
 - redox alteration of lipids, 190
 - segmental vitiligo, 190, 191
 - stressed melanocytes, 190
 - Patients' perspectives
 - associations, 461–462
 - care schemes, 459
 - doctor-patient relationship, 458–459
 - doctors perceptions, 457
 - factors, 457
 - holistic care for sufferers, 457–458
 - issues, 458
 - phototherapy, 458–459
 - transitional care
 - corrective makeup, 460–461
 - drug-based treatments, 459–460
 - psychological care, 460
 - sunscreen cover, 461
 - Pattern recognition receptors (PRRs), 291
 - PBMCs, *see* Peripheral blood mononuclear cells
 - P-cadherin, 268, 269
 - Perceived severity, 175, 176, 346, 452
 - Perifollicular repigmentation, 174
 - Perilesional hypopigmentation, 439
 - Periocular vitiligo, 445
 - Perioral vitiligo, 445–446
 - Peripheral blood mononuclear cells (PBMCs), 228, 257, 281
 - Personalized stratified approach, 476, 477
 - Phenolic catecholic derivatives, 122
 - 88% Phenol solution, 385
 - L-Phenylalanine, 134, 372
 - Photoprotection issues
 - normal and vitiligo skin UV sensitivity, 430–431
 - practical photoprotection, 433–434
 - skin cancer, 432–433
 - UV irradiation, 431–432
 - Phototherapy, 292–293
 - Phototherapy chamber or with sunlight (PUVASOL), 441
 - Phytophotodermatitis, 8
 - Piebaldism, 14–17, 132
 - Pigmentary mosaicism, 335
 - Pimecrolimus, 348, 356, 358, 359, 440
 - Plant-derived extracts, 465
 - Pmel-1 mouse model, 217
 - Point-counting method, 197
 - Poliosis, 95, 97
 - Polyclonal antibodies, 232
 - Polypodium leucotomos*, 349, 370, 373, 415, 465
 - POMC, *see* Proopiomelanocortin
 - Post-inflammatory hypomelanoses, 18, 19
 - Posttraumatic leukoderma, 21
 - Predictive assessment, 183
 - Premature canities, 97
 - Premature hair graying, 94, 98, 99, 170, 183
 - Principal component analysis, 197
 - Programmed cell death-1 (PD-1), 164, 165
 - Proopiomelanocortin (POMC), 279
 - agouti signaling protein, 309
 - α -MSH, 308
 - β -endorphin plasma levels, 307, 308
 - Furin convertase, 308
 - hypothalamic-pituitary-adrenal, 307
 - MC1R*, 308, 309
 - mRNA levels, 308
 - Prooxidants, 278–281
 - Propionibacterium acnes*, 21
 - Prostaglandins, 467
 - Protein equalization, 234
 - Proteomics, 233–234
 - Pseudocatalase (PC), 349, 365–366, 387
 - Psoralea corylifolia*, 7, 8
 - Psoralen and ultraviolet A (PUVA) phototherapy
 - GVHD, 96–97
 - mycosis fungoides, 96
 - Psoriasis, 128
 - Psychiatric morbidity, 154, 178, 452
 - Psychological factors, 175
 - Psychological interventions
 - cognitive-behavioural therapy, 453
 - perceived severity, 452
 - prevalence, 452
 - screening patients, 452
 - Psychosocial effects, 178
 - PTPN22* gene, 241
 - PUVA therapy, 9
- Q**
- Q-switched alexandrite (QSA) laser, 386–387
 - Q-switched ruby (QSR) laser, 386
 - Quality of life (QoL)
 - DLQI, 179
 - historical perspective, 177–178
 - psychological stress, 179
 - psychosocial effects, 178
 - socio-economic and educational consequences, 178–179
 - vitiligo impact scale, 179
- R**
- Reactive oxygen species (ROS), 189–190, 278–281
 - ReCell® kit, 390, 391
 - Reflectance spectroscopy
 - colorimetric examination, 198
 - DermaSpectrometer, 199
 - erythema index, 198
 - melanin index, 198
 - Mexameter, 199
 - tristimulus colorimeter, 198
 - Regenerative medicine, 483
 - Relative melanin index (RMI), 199

- Repigmentation
 anatomical factors, 471
 Erbium-YAG laser, 473
 follicular melanocytes, 470
 lesion size, 472
 marginal melanocytes, 470
 pathological factors, 471
 sources, 470–471
 stabilization, 475–476
 timing of surgery, 474
- RNA-induced silencing complex (RISC), 255
- ROS, *see* Reactive oxygen species
- “Rule of nines,” 196
- S**
- Salicylates, 434
- SBEG, *see* Suction blister epidermal grafting
- Scalp vitiligo, 446
- Schmidt (APS2) syndrome, 135
- Schwann cell precursors (SCPs), 267
- SCORAD index, 170
- Scoring/grading methods
 global assessment scale, 196
 point-counting method, 197
 “rule of nines,” 196
 VASI, 196, 197
 VIDA score, 196, 197
- Scoring system, 172–174
- Secreted frizzled-related protein 1 (SFRP1) gene, 261
- Segmental vitiligo (SV)
 alpha-and beta-adrenoreceptor response, 56
 bilateral involvement, 63–65
 blaschkolinear/developmental hypothesis, 56
 blaschkolinear distribution patterns, 56–58
 body leukotrichia, 60
 causes, 54
 cephalic SV, 61–62
 classification, 61
 clinical and pathological features, 58–60
 depigmentation of hairs, 61
 dermatomal/neural hypothesis, 54
 eyebrow and eyelashes, 61
 helium-neon (He-Ne) laser, 67
 immunologic mechanisms, 54
 ischemic depigmentation, 55
 Koga’s experiments, 54, 56
 leukotrichia-associated SV, 61
 NBUVB, 65–67
 neural mechanisms, 334
 and nevus spilus, 57, 59
 vs. non-segmental forms, 334
 microvascular skin homing, 335
 physostigmine-induced sweating response, 56
 prevalences, 333
 poliosis, 61
 PUVA treatment, 65–66
 recurrence of vitiliginous lesions, 62, 63
 repigmentation, 65–66
 similar segmental distribution, 54, 55
 somatic mosaicism, 56, 58, 334–335, 340
 sympathetic anomalies, 56
 sympathetic denervation, 55
 tacrolimus ointment, 67–68
 treatment, 68
 of trunk, 62, 63
 twin-spotting phenomenon, 57
 white macule, 63, 64
- Senescence-associated secretory phenotype (SASP), 279
- Serum lipidomics, 234
- Sexual relationship, 178
- Shirabito, 4
- Shweta kustha, 178
- Single-nucleotide polymorphisms (SNPs), 242, 246
- Sirtuins, 280
- 6-well plate technique, 391
- Sjögren’s syndrome, 84
- Skin biopsy, 172
- Skin-derived precursors (SKPs), 325
- Skin melanocytes
 cellular origin, 266–267
 melanoblasts
 cadherins, 268, 269
 dorsolateral pathway, 266, 267
 dorsoventral pathway, 266
 keratinocyte stem cells, 267
 melanocyte progenitors migratory pathway, 266
 melanocyte stem cells, 267
 skin distribution and differentiation, 269
- Skin melanogenic unit, 339
- Skin of color
 clinical subtypes of vitiligo, 156
 depigmentation therapy, 158–159
 etiology and pathogenesis, 155–156
 quality of life, 154–155
 treatment, 157–158
- Slide-based cytometry (SBC), 233
- Smyth line (SL) chicken, 259
 alopecia areata-like feathering defect, 213
 autoimmune hypothyroiditis, 212
 avian model, 213
 blindness, 212
 characteristics, 207
 environmental factor, 211–212
 genetics basis, 208–209
 immune system, 209–211
 impaired vision, 212
 inherent melanocyte alterations, 211
 spontaneous autoimmune vitiligo, 207–209
 uveitis, 212
- Social isolation, 178, 452
- Social status of vitiligo patients, 6–7
- Socio-economic and educational consequences, 178–179
- Solar simulated radiation (SSR), 430–431
- Soybean trypsin inhibitor, 391
- Spreading, 173, 174
- SSR, *see* Solar simulated radiation
- Staging, of vitiligo, 172–174
- Statins, 466
- Stem cell factor (SCF), 330
- Stratum corneum (SC), 430, 431
- Suction blister epidermal grafting (SBEG), 441, 444, 445
- Sun-protective factor (SPF), 433–434
- Sun-reactive skin phototypes (SPT), 430

- Sunscreen cover, 461
 Suprabasal melanocytes, 272
 Surgical therapies, 348
 cellular grafting
 cultured epidermal sheet transplantation, 384–385
 cultured melanocyte transplantation, 383–384
 types, 382, 383
 vitiliginous recipient sites, 382
 history, 9
 NCES
 basal cell layer suspension, 387
 culture medium and xenobiotics, 385–386
 donor skin, 386
 factors influencing outcome, 389–390
 hyaluronic acid, 387
 hypopigmentation, 386
 laser ablation, 386
 long-term follow-up, 386–387
 protocol, 395–396
 simplification, 390–392
 ultrathin epidermal graft, 388–389
 UVB stimulation, 387–388
 wound healing, 386
 NCORSHFS transplantation, 392–395
 SV, *see* Segmental vitiligo
 SvetaKhista, 4
 Sweat secretion stimulation test, 54
 Symptomatic inflammation, 184
 Syndromic vitiligo, 183
 Systematic pathology assessment, 183
 Systemic antioxidants, 372–374
 Systemic lupus erythematosus (SLE), 259
 Systemic oxidative stress, 281
 Systemic sclerosis (SSC), 259
- T**
 Tacrolimus, 356, 357, 359, 413, 439–440
 T cell skin recruitment blocking strategy, 370–371
 T cell subset imbalance, 290
 T cell trafficking, 290–291
 TCI, *see* Topical calcineurin inhibitors
 TCS, *see* Topical glucocorticosteroids
 T1D susceptible genes, 260
 12-*O*-Tetradecanoylphorbol-13-acetate (TPA), 383
 Th1/Th2 predominant diseases, 182
 3D-cultured skin system, 322–323
 Thyroglobulin, 172
 Thyroid peroxidase (TPO), 172
 Toll-like receptors (TLRs), 291
 Topical calcineurin inhibitors (TCI), 348
 application scheme, 359–361
 for atopic dermatitis, 356
 beneficial effect, 356
 case reports and clinical studies, 357
 combined therapies, 348, 357, 359
 in combination with UVB, 357, 358
 for inflammatory skin diseases, 356
 interpretation, 353–354
 pimecrolimus, 356, 358, 359
 side effects, 361–362
 tacrolimus monotherapy, 357, 359
 therapeutic options, 359
 TNF α production, 356
 topical corticosteroids, 354
 Topical corticosteroids (TCS)
 application scheme, 353, 355
 betamethasone, 355
 fluticasone, 352, 355
 fluticasone propionate, 352
 hypermelanoses treatment, 354
 intralesional therapy, 354
 mechanism of glucocorticoid action, 354
 NSV, 349
 side effects, 355–356
 skin atrophy, 351
 steroid clobetasol dipropionate, 355
 TCS, 351
 with tretinoin and hydroquinone, 354
 Topical glucocorticosteroids (TCS), 353–354
 Topical therapies, 348
 antioxidants, 349
 calcineurin inhibitors, 351
 combination therapy, 352–353
 pseudocatalase, 414
 tacrolimus and pimecrolimus, 352–353
 topical corticosteroids
 fluticasone, 352
 fluticasone propionate, 352
 NSV, 349
 side effects, 353
 skin atrophy, 351
 TCS, 351
 vitamin D analogues, 414
 Traditional Chinese medicine, 464–465
 Transcriptomics, 235
 Transgenesis, 228
 Transit amplifying cells (TAC), 267
 T regulatory cells (Tregs), 190, 304
 Tristimulus colorimeter, 198
 TRP1 transgenic mouse model, 218
 Tuberous sclerosis, 14, 17
 Two-dimensional differential image-gel electrophoresis (2D-DIGE), 233
 Type 1 diabetes (T1D), 260
 Tyrosine-related protein (TRP)-1, 279, 280
- U**
 Ubiquitin-associated and SH3 domain-containing A protein (UBASH3A), 287
 Ultraviolet (UV) treatments, 347–348
 3' Untranslated region (3' UTR), 255, 256
- V**
 VASI, *see* Vitiligo area scoring index
 VDR, *see* Vitamin D receptors
 VETF, *see* Vitiligo European Task Force
 Vinay Pitak, 4
 Vitamin B12, 97
 Vitamin C, 386
 Vitamin D, 414
 Vitamin D analogues, 362–364, 414

- Vitamin D receptors (VDR), 155
 Vitamin E, 372–373
 Vitamin supplementation, 157, 372
 Vitesse mouse model, 219
 Vitiligo area scoring index (VASI), 194, 196, 197
 Vitiligo disease activity (VIDA) score,
 194, 196, 197, 202
 Vitiligo during pregnancy, 146–147
 Vitiligo European Task Force (VETF),
 12, 170, 172, 195, 287, 346
 Vitiligo fibroblasts, 330
 Vitiligo Global Issues Consensus Conference
 (VGICC), 12
 Vitiligo impact scale (VIS), 179
 Vitiligo-like depigmentation,
 94, 96, 164–166, 214, 215
 Vitiligo locations
 elbows, knees, hands, and feet, 446, 447
 genital vitiligo, 446
 periocular vitiligo, 445
 perioral vitiligo, 445–446
 scalp vitiligo, 446
 Vitiligo minor/hypochromic vitiligo, 14
 Vitiligo punctata, 14
 Vitiligo specific quality of life (vitiQoL), 154, 179
 Vitiligo-specific quality of life measurement
 (VIS-22), 154
 Vitiligo universalis (VU), 13
 autoimmune/autoinflammatory disorders, 48
 clinical features, 46, 47
 clinical manifestation, 45
 diagnosis, 48
 management, 49
 MBEHQ, 48
 non-segmental vitiligo, 45
 oral beta-carotene, 48
 precipitating factors, 46–48
 prevalence, 45, 46
 true segmental vitiligo (SV), 45
 Vitiligo vulgaris, 13
 Vitix[®], 366
 Vogt-Koyanagi-Harada (VKH) syndrome,
 48, 82, 83, 109, 182, 183, 213, 218
 VU, *see* Vitiligo universalis
- W**
- Waardenburg’s syndrome (WS), 14, 18, 109
 Water buffalo, 213
 White leprosy, 5
 Wnt/betacatenin pathway, 483
 WNT pathways, 331
 “Wood’s filter,” 194
 Wood’s lamp, 170, 171, 174, 194, 195
 Wood’s light
 examination, 194–195
 follow-up, 476
 World vitiligo day, 179
- Z**
- Zoorat, 4, 5